Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice

Valeria Cento; Monica Tontodonati; Velia Chiara Di Maio; Maria Concetta Bellocchi; Fabrizio Valenti; Alessandra Manunta; Serena Fortuna; Daniele Armenia; Luca Carioti; Francesco Paolo Antonucci; Ada Bertoli; Francesca Trave; Pierluigi Cacciatore; Mario Angelico; Pierluigi Navarra; Avidan U. Neumann; Jacopo Vecchiet; Giustino Parruti; Sergio Babudieri; Carlo Federico Perno; Francesca Ceccherini-Silberstein

doi:10.1016/j.dld.2014.12.004

Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice

Valeria Cento
, Monica Tontodonati
, Velia Chiara Di Maio
, Maria Concetta Bellocchi
, Fabrizio Valenti
, Alessandra Manunta
, Serena Fortuna
, Daniele Armenia
, Luca Carioti
, Francesco Paolo Antonucci
, Ada Bertoli
, Francesca Trave
, Pierluigi Cacciatore
, Mario Angelico
, Pierluigi Navarra
, Avidan U. Neumann
, Jacopo Vecchiet
, Giustino Parruti
, Sergio Babudieri
, Carlo Federico Perno

Francesca Ceccherini-Silberstein

University of Rome Tor Vergata
Pescara General Hospital
University of Sassari
Bar-Ilan University
Infectious Disease Clinic

Risultato della ricerca: Contributo in rivista › Articolo

4 Citazioni (Scopus)

Abstract

The used first generation protease inhibitors may be hampered by virological failure in partially interferon-sensitive patients.

Lingua originale	Inglese
pagine (da-a)	233-241
Numero di pagine	9
Rivista	Digestive and Liver Disease
Volume	47
DOI	https://doi.org/10.1016/j.dld.2014.12.004
Stato di pubblicazione	Pubblicato - 2015

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Keywords

Aged
Antiviral Agents
Drug Resistance, Viral
Drug Therapy, Combination
Drug-resistance
Female
Genotype
Hepacivirus
Hepatitis C, Chronic
Humans
Interferon-alpha
Linear Models
Male
Mathematical modelling
Middle Aged
Mutation
Oligopeptides
Protease Inhibitors
Protease inhibitors
RNA Stability
RNA, Viral
Ribavirin
Treatment Outcome
Viral Load
Viral kinetic
Virus Replication

Accesso al documento

10.1016/j.dld.2014.12.004

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Cento, V., Tontodonati, M., Di Maio, V. C., Bellocchi, M. C., Valenti, F., Manunta, A., Fortuna, S., Armenia, D., Carioti, L., Antonucci, F. P., Bertoli, A., Trave, F., Cacciatore, P., Angelico, M., Navarra, P., Neumann, A. U., Vecchiet, J., Parruti, G., Babudieri, S., ... Ceccherini-Silberstein, F. (2015). Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice. Digestive and Liver Disease, 47, 233-241. https://doi.org/10.1016/j.dld.2014.12.004

@article{3542a361960040149647fb5d5b4ed0ff,

title = "Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice",

abstract = "The used first generation protease inhibitors may be hampered by virological failure in partially interferon-sensitive patients.",

keywords = "Aged, Antiviral Agents, Drug Resistance, Viral, Drug Therapy, Combination, Drug-resistance, Female, Genotype, Hepacivirus, Hepatitis C, Chronic, Humans, Interferon-alpha, Linear Models, Male, Mathematical modelling, Middle Aged, Mutation, Oligopeptides, Protease Inhibitors, Protease inhibitors, RNA Stability, RNA, Viral, Ribavirin, Treatment Outcome, Viral Load, Viral kinetic, Virus Replication, Aged, Antiviral Agents, Drug Resistance, Viral, Drug Therapy, Combination, Drug-resistance, Female, Genotype, Hepacivirus, Hepatitis C, Chronic, Humans, Interferon-alpha, Linear Models, Male, Mathematical modelling, Middle Aged, Mutation, Oligopeptides, Protease Inhibitors, Protease inhibitors, RNA Stability, RNA, Viral, Ribavirin, Treatment Outcome, Viral Load, Viral kinetic, Virus Replication",

author = "Valeria Cento and Monica Tontodonati and \{Di Maio\}, \{Velia Chiara\} and Bellocchi, \{Maria Concetta\} and Fabrizio Valenti and Alessandra Manunta and Serena Fortuna and Daniele Armenia and Luca Carioti and Antonucci, \{Francesco Paolo\} and Ada Bertoli and Francesca Trave and Pierluigi Cacciatore and Mario Angelico and Pierluigi Navarra and Neumann, \{Avidan U.\} and Jacopo Vecchiet and Giustino Parruti and Sergio Babudieri and Perno, \{Carlo Federico\} and Francesca Ceccherini-Silberstein",

year = "2015",

doi = "10.1016/j.dld.2014.12.004",

language = "English",

volume = "47",

pages = "233--241",

journal = "Digestive and Liver Disease",

issn = "1590-8658",

}

Cento, V, Tontodonati, M, Di Maio, VC, Bellocchi, MC, Valenti, F, Manunta, A, Fortuna, S, Armenia, D, Carioti, L, Antonucci, FP, Bertoli, A, Trave, F, Cacciatore, P, Angelico, M, Navarra, P, Neumann, AU, Vecchiet, J, Parruti, G, Babudieri, S, Perno, CF & Ceccherini-Silberstein, F 2015, 'Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice', Digestive and Liver Disease, vol. 47, pagg. 233-241. https://doi.org/10.1016/j.dld.2014.12.004

TY - JOUR

T1 - Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice

AU - Cento, Valeria

AU - Tontodonati, Monica

AU - Di Maio, Velia Chiara

AU - Bellocchi, Maria Concetta

AU - Valenti, Fabrizio

AU - Manunta, Alessandra

AU - Fortuna, Serena

AU - Armenia, Daniele

AU - Carioti, Luca

AU - Antonucci, Francesco Paolo

AU - Bertoli, Ada

AU - Trave, Francesca

AU - Cacciatore, Pierluigi

AU - Angelico, Mario

AU - Navarra, Pierluigi

AU - Neumann, Avidan U.

AU - Vecchiet, Jacopo

AU - Parruti, Giustino

AU - Babudieri, Sergio

AU - Perno, Carlo Federico

AU - Ceccherini-Silberstein, Francesca

PY - 2015

Y1 - 2015

N2 - The used first generation protease inhibitors may be hampered by virological failure in partially interferon-sensitive patients.

AB - The used first generation protease inhibitors may be hampered by virological failure in partially interferon-sensitive patients.

KW - Aged

KW - Antiviral Agents

KW - Drug Resistance, Viral

KW - Drug Therapy, Combination

KW - Drug-resistance

KW - Female

KW - Genotype

KW - Hepacivirus

KW - Hepatitis C, Chronic

KW - Humans

KW - Interferon-alpha

KW - Linear Models

KW - Male

KW - Mathematical modelling

KW - Middle Aged

KW - Mutation

KW - Oligopeptides

KW - Protease Inhibitors

KW - Protease inhibitors

KW - RNA Stability

KW - RNA, Viral

KW - Ribavirin

KW - Treatment Outcome

KW - Viral Load

KW - Viral kinetic

KW - Virus Replication

KW - Aged

KW - Antiviral Agents

KW - Drug Resistance, Viral

KW - Drug Therapy, Combination

KW - Drug-resistance

KW - Female

KW - Genotype

KW - Hepacivirus

KW - Hepatitis C, Chronic

KW - Humans

KW - Interferon-alpha

KW - Linear Models

KW - Male

KW - Mathematical modelling

KW - Middle Aged

KW - Mutation

KW - Oligopeptides

KW - Protease Inhibitors

KW - Protease inhibitors

KW - RNA Stability

KW - RNA, Viral

KW - Ribavirin

KW - Treatment Outcome

KW - Viral Load

KW - Viral kinetic

KW - Virus Replication

UR - http://hdl.handle.net/10807/70696

U2 - 10.1016/j.dld.2014.12.004

DO - 10.1016/j.dld.2014.12.004

M3 - Article

SN - 1590-8658

VL - 47

SP - 233

EP - 241

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

ER -

Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice

Abstract

OSS delle Nazioni Unite

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo